The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients

BMJ Open

Volumn 3, Issue 1, 2013, Pages

  Ali, Shehzad ^a   Mealing, Stuart ^a   Hawkins, Neil ^a,b   Lescrauwaet, Benedicte ^c   Bjork, Stefan ^d   Mantovani, Lorenzo ^e   Lampertico, Pietro ^f  

^a ICON PLC   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c Xintera Consulting Bvba   (Belgium)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CHRONIC PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INDIVIDUAL PATIENT LEVEL DATA; MAJOR CLINICAL STUDY; PATIENT CODING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84873470089     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001309     Document Type: Article

References (17)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
2. British National Formulary. http://www.bnf.org/bnf/ (accessed 16 Jan 2012).
3. Caldwell D, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2007;331:897-900. (Pubitemid 41502718)
4. Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956-64.
5. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19. (Pubitemid 43197227)
6. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. (Pubitemid 39334902)
7. Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147.
8. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analysis. Gastroenterology 2010;139:1218-29.
9. Dakin HA, Fidler C, Harper CH. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos (t) ides for treatment of nucleos (t) ide-naive patients with chronic hepatitis B. Value Health 2010;13:934-45.
10. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. (Pubitemid 43357805)
11. Chang TT, Gish RG, de MR, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10. (Pubitemid 43357804)
12. Maxwell SE, Delaney HD. Designing experiments and analyzing data: a model comparison perspective. Taylor & Francis Group, Lawrence Erlbaum, 2004.
13. Colonno RJ, Rose FE, Baldick CJ, et al. High barrier to resistance results in no emergence of entecavir resistance in nucleoside-nave subjects during the first two years of therapy. J Hepatol 2006;44(Suppl 2):S182.
14. National Institute for Health and Clinical Excellence. Final appraisal determination: Entecavir for the treatment of chronic hepatitis B. http://www.nice.org.uk/nicemedia/pdf/EntecavirFinalFAD.pdf (accessed 16 Jan 2012).
15. Dakin HA, Bentley A, Dusheiko GM. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health 2010;13:922-33.
16. Veenstra DL, Sullivan SD, Clarke L, et al. Cost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B based on a 2-year clinical trial. Pharmacoeconomics 2007;25:963-77. (Pubitemid 350014529)
17. Veenstra DL, Sullivan SD, Dusheiko GM, et al. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients woth HBe-antigen-positive chronic hepatitis B in the UK. Eur J Gastroenterol Hepatol 2007;19:631-38. (Pubitemid 47067060)